ResMed Inc RMD.ASX

ResMed Inc is an American medical equipment company that provides devices to assist patients with sleep apnoea and other respiratory conditions. Founded in 1989, the firm is based in San Diego, California, and has an international customer base.

ResMed develops, manufactures, distributes and markets cloud-based software applications and medical devices for the healthcare markets. The company’s business is operated through two segments: Sleep and Respiratory Care, and Software as a Service. The company offers a range of solutions and products to address respiratory disorders, including diagnostic products, mask systems, ventilation devices and cloud-based software to manage patient outcomes. Some of the company’s software solutions include AirView, which enables remote monitoring and configuration of patient devices; myAir, a personalised sleep apnoea therapy management application for patients; and U-Sleep, a compliance monitoring solution.

In October 2021, ResMed announced the acquisition of Ectosense, the maker of the cloud-connected NightOwl Home Sleep Test. ResMed has been a minority investor in Ectosense since July 2020. With this acquisition, ResMed plans to increase the number of regions where NightOwl is offered. Since December 1999, stock for ResMed has been listed on the Australian Securities Exchange under the ticker RMD.

Add RMD stock to your eToro watchlist to follow the latest news and share price movements.